Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 145.08%.
Infravalorada
El PE más reciente de la empresa es -36.41, en un rango percentil bajo de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 80.14M acciones, lo que supone un aumento del 3.51% con respecto al trimestre anterior.
En posesión de HACAX
El inversor estrella HACAX posee 28.88K acciones de este valor.
Mayor actividad del mercado
La empresa está generando mayor interés entre los inversores, con una relación de rotación de 20 días del 0.49.